1 March 2018 – Luis Iglesias will become Head of Santen EMEA (Geneva) from 1 April 2018, as a successor to Shigeo Taniuchi who will return to Japan to become President and Chief Operating Officer of the parent company, Santen Pharmaceutical Co., Ltd.
When Luis joined Santen in September 2017 as Senior Vice President, Commercial – EMEA, he brought with him more than twenty five years’ experience in pharmaceuticals in Europe and the US, with a particular specialism in ophthalmology and medical devices.
Luis commented: "I am passionate about focusing on our customers, be they patients or healthcare professionals. Serving them to the best of our abilities will make us a great company.
I am honoured to accept this role and I look forward to working with my wonderful colleagues as we directly contribute to the achievement of our long-term strategic Vision 2020 to become a specialized ophthalmology company with a global presence."
In recent years Santen has transformed and expanded significantly from a Japan-centric company to one of the leading global companies in ophthalmology with growing presence in many countries outside Japan.
For more information please contact Siân Boisseau,
firstname.lastname@example.org +44 7710 022804 or Garrett Karaaziz,
email@example.com, +44 7951 449541.
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more information, please visit Santen websites
www.santen.com (Japan headquarters) and